Home Compare AZN.L vs STE
Stock Comparison · Structural lead, mixed market

AstraZeneca vs STERIS: Which Stock Looks Stronger in 2026?

The structural profiles are close, with AstraZeneca carrying a narrow edge on profitability. STERIS still has the edge on valuation, which keeps the comparison from looking entirely one-sided. On the market side, AstraZeneca is in better shape — its trend is intact while STERIS's trend has broken down. That puts structure and market broadly in agreement — AstraZeneca's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the lead runs through profitability, while valuation acts as a real counterweight.

Trajectory Similarity
0.61
Moderately similar
Peer-set rank: #11
within AstraZeneca PLC's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

Most of the shared profile comes through revenue stability and margin trend.

Similarity drivers
revenue stabilitymargin trend
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
AZN.L
AstraZeneca PLC
49
Peer-Score
Signal qualityHigh
vs
STE
STERIS plc
48
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AZN.L vs STE Profitability 41 22 Stability 65 69 Valuation 39 58 Growth 59 50 AZN.L STE
Gap Ranking
#1 Profitability +19
#2 Valuation +19
#3 Growth +9
#4 Stability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AZN.L and STE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AZN.LSTE Relative valuation Structural strength

AstraZeneca PLC still looks stronger overall, though current pricing looks more supportive for STERIS plc.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Profitability also leans toward AstraZeneca PLC, reinforcing the broader structural lead.
Valuation
On valuation, STERIS plc is positioned higher in the group, while AstraZeneca PLC is closer to the middle.
Profitability — Dominant Gap
AZN.L
41
STE
22
Gap+19in favour of AZN.L

Capital efficiency adds support, with a 11.3-point ROIC advantage.

What keeps the gap from being one-sided

There is still a strong counterforce in valuation, so the lead stays clear without becoming a sweep.

What this means for the comparison

The lead is there, but one opposing signal still keeps the comparison balanced.

Explore full peer positioning in AssetNext

Break down the AZN.L vs STE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-valuation comparisons

Explore how AZN.L and STE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.